Core Insights - Dapu Biotech has completed a Series B2 financing round led by the Intellectual Property Fund under Shanghai Science and Technology Innovation Group, aimed at accelerating the global commercialization of its high-end life science instruments and promoting the integration of AI with drug discovery and synthetic biology innovation [2][3] Company Overview - Founded in 2018 and incubated at the Hong Kong University of Science and Technology, Dapu Biotech is a leading company in droplet microfluidics in China, dedicated to providing world-class life science tools [2] - The company has established R&D, business, and production centers in Shenzhen, Shanghai, and Jiashan, along with a laboratory in San Diego, USA, employing nearly 100 R&D personnel [2] Product Development - Dapu Biotech has developed and commercialized over ten products, including the Cytospark® high-throughput antibody screening system and the OMNI drop® versatile droplet microfluidic analysis system, addressing key pain points in drug discovery and synthetic biology from R&D to production [3] - These products are widely used in various fields such as antibody drug development, enzyme directed evolution, synthetic biology research, high-throughput screening, tumor research, early screening and precision treatment, non-invasive prenatal diagnosis, virus quantification, and biopharmaceutical quality control [3] Market Position - Dapu Biotech has provided products and technical support to over 200 leading biopharmaceutical companies, synthetic biology firms, CXO service providers, and renowned universities and research institutions globally, achieving significant breakthroughs in multiple areas [3]